Journal
HEPATOLOGY RESEARCH
Volume 45, Issue 10, Pages E1-E11Publisher
WILEY
DOI: 10.1111/hepr.12459
Keywords
clinical trials; hepatocellular carcinoma; molecularly targeted therapy; novel agents; sorafenib
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology-Japan
- Ministry of Health, Labor and Welfare-Japan
- Japan Health Sciences Foundation
- Grants-in-Aid for Scientific Research [26670375] Funding Source: KAKEN
Ask authors/readers for more resources
Hepatocellular carcinoma (HCC) can be lethal due to its aggressive course and lack of effective systemic therapies for advanced disease. Sorafenib is the only systemic therapy that has demonstrated an overall survival benefit in patients with advanced HCC, and new agents for treatment of advanced HCC are needed. The multiple pathways involved in HCC oncogenesis, proliferation and survival provide many opportunities for the development of molecularly targeted therapies. Molecular targets of interest have expanded from angiogenesis to cancer cell-directed oncogenic signaling pathways for treatment of advanced HCC. Agents targeting vascular endothelial growth factor receptor, epidermal growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, c-mesenchymal-epithelial transition factor-1 and mammalian target of rapamycin signaling have been actively explored. This article focuses on the evaluation of molecular agents targeting pathogenic HCC and provides a review of recently completed phase III drug studies (e.g. involving sorafenib, sunitinib, brivanib, linifanib, erlotinib, everolimus, ramucirumab or orantinib) and ongoing drug studies (e.g. involving lenvatinib, regorafenib, tivantinib or cabozantinib) of molecularly targeted agents in advanced HCC, including a brief description of the biologic rationale behind these agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available